Bristol-Myers Squibb (BMY) Says EC Approved its Opdivo Four-Week Dosing Schedule for Advanced Melanoma and Previously Treated Renal Cell Carcinoma
April 25, 2018 4:37 PM
Bristol-Myers Squibb Company (NYSE: BMY) today announced that the European Commission (EC) has approved an every four-week (Q4W) Opdivo (nivolumab) ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
